Fig. 4From: Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective studyChange in anti-sRBD IgG titre at V1, V2, V3, and V4 (X: sampling time; Y: NAbs %inhibition)Back to article page